Medicis announces new patents for Solodyn 90mg

May 26, 2009

By Flinn Foundation

[Source:] – Medicis Pharmaceutical Corp. Tuesday announced two new patents for its Solodyn 90mg tablet. The patents include subject matter covering methods of using the 90mg controlled-release oral dosage form of minocycline to treat acne and the composition of the 90mg dosage form. Both patents will expire in 2027.

The Scottsdale, Arizona-based specialty pharmaceutical company launched Solodyn in July 2006. The tablet is approved for once daily dosage in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

For more information click here.